As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma

作者：Desaki Ryosuke; Sawada Genta; Okumura Hiroshi^*; Ikeda Ryuji; Tanabe Kan; Komatsu Hisateru; Mimori Koshi; Mori Masaki; Kita Yoshiaki; Uchikado Yasuto; Arigami Takaaki; Uenosono Yoshikazu; Owaki Tetsuhiro; Ishigami Sumiya; Natsugoe Shoji

来源：Annals of Surgical Oncology, 2017, 24(2): 586-593.

DOI：10.1245/s10434-015-5031-0

Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer.
The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used.
Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor.
As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.

• 出版日期2017-2